International Clinical Trial: Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124468) titled 'Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants' on Aug. 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Infections

Intervention: Drug: Meropenem-Pralubactam

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 2025

Target Sample Size: 16

To know more, visit https://clinicaltrial...